Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Allenamento a intervalli ad alta intensità nel trattamento dell'ipercolesterolemia familiare (UPPA-FH) (UPPA-FH)

18 settembre 2026 aggiornato da: José Antonio Vargas Hitos, Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental

Svelare il potenziale dell'attività fisica nel trattamento dell'ipercolesterolemia familiare: impatto dell'esercizio fisico sulla forma fisica cardiorespiratoria, nella progressione dell'aterosclerosi e nei meccanismi sottostanti

This study has one main objective:

a) To assess the impact of two different supervised exercise interventions on cardiorespiratory fitness and markers of subclinical atherosclerosis in patients with Familiar Hipercolesterolemia (FH), and to unravel the underlying mechanisms behind these effects.

The starting hypothesis of the UPPA-FH project anticipates that both exercise interventions will produce a large increase in cardiorespiratory fitness and will improve significant markers of atherosclerosis in patients with FH, with high-intensity interval training program (HIIT) being more efficient than the moderate-intensity continuous training (MICT) modality. The main effects will be mediated by a significant change in the metabolomic signature of the participants. In addition, higher physical activity will be associated with more favorable markers of atherosclerosis progression, as shown through blood and image technique

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Familial hypercholesterolemia (FH) is an inherited disorder characterized by high levels of LDL cholesterol and an increased risk of atherosclerosis and premature cardiovascular disease. From a clinical perspective, FH patients require lifelong management and monitoring of their cholesterol levels and may require multiple medications to control their cholesterol levels, leading to increased healthcare utilization and costs. From an economic perspective, the lifetime costs of managing FH can be significant and can include the cost of medications, diagnostic tests, and hospitalizations for cardiovascular events. In Spain, FH represents a heavy burden for the health care system, with direct costs of 37,299,000 €, indirect costs (due to loss of labor productivity) of 50,049,000 €, and an average of 25 years of life lost adjusted for labor productivity. From a public health perspective, FH affects around 25 million people worldwide that are at an increased risk of premature mortality, making FH a significant public health concern.

Hypercholesterolemia is one of the main vascular risk factors (VRF) related to the development of cardiovascular diseases (CVD), mainly myocardial infarction (MI) and stroke, the main causes of global mortality in the past decades. It is important to note that patients with FH present an increased prevalence of CVD at a very early age (44 years on average) and, in comparison to the general population, patients with FH have a 13.2 times higher risk of developing atherosclerotic CVD; specifically, up to 50% of men and 30% of women with FH will suffer an MI before the age of 60. Atherosclerosis is a complex process that involves endothelial dysfunction, inflammation, or oxidative stress. The presence of atherosclerosis can be assessed with positron emission tomography (PET), which has shown a high ability to predict the development of atherosclerotic plaque and cardiovascular events even after the consideration of classic VRF, so it is used as a method of early diagnosis of subclinical atherosclerosis in patients with chronic proinflammatory diseases. Therefore, the use of PET along with various plasma markers of inflammation in patients with FH (including C-reactive protein, [CRP], interleukin 10 [IL10], oxidized LDL [oxLDL], and the intracellular adhesion molecule 1 [ICAM1]), could allow the detection of atherosclerotic disease in the very early stages. Consequently, understanding novel markers that allow early identification of subclinical atherosclerosis, as well as strategies for reducing the VRF associated with FH, are key targets in these patients.

The treatment of hypercholesterolemia is primarily based on pharmacological therapies such as statins, ezetimibe, and monoclonal antibodies, which can decrease LDL cholesterol levels by up to 60%. However, the rate of achieving LDL cholesterol targets set by clinical practice guidelines is low (30-40%) due to poor tolerance to high doses of statins and other reasons. Importantly, new risk factors such as chronic vascular inflammation and oxidative stress are now considered in the etiology of atherosclerotic CVD beyond LDL cholesterol levels. Consequently, new treatment approaches are needed to address the treatment of FH as an important public health concern.

For all the above, unraveling the role of potential protective factors and interventions that might significantly improve the cardiometabolic profile and reduce the risk of morbi-mortality in this population, as well as the mechanisms involved, is of wide clinical and public health interest.

The UPPA-FH project will unravel the role of physical activity and different exercise interventions on critical health markers in men and women with FH and will study the mechanisms by which these effects are produced. For instance, whether the effects of exercise are mediated by changes in the metabolomic signature related to blood lipids will be explored. This will enable i) international institutions to develop clinical guidelines including exercise as a first-line treatment for the management of FH and ii) to unravel (for the first time) the potential mechanisms behind the effects of exercise in this population.

Physical activity and physical fitness are strong markers of health that are positively and strongly associated with survival in the general population and in patients with CVD. However, the role of physical activity on markers of atherosclerosis progression, inflammation, endothelial function, and other CVD risk factors in patients with FH has not been explored and would provide a framework for targeted physical activity promotion interventions. Similarly, CRF is associated with a better lipid profile, lower rates of pro-atherosclerotic VRF (hypertension, diabetes), and less subclinical atherosclerosis in different populations and is associated with a lower risk of death from all causes and a lower risk of death from cardiovascular diseases (CVD). CRF has also been shown to be a better predictor of mortality than other traditional vascular risk factors (VRF), such as hypercholesterolemia, hypertension, smoking, or type 2 diabetes. In men with hypercholesterolemia, higher cardiorespiratory fitness (CRF) is associated with up to 45% lower risk of CVD mortality, independent of other clinical risk factors, which underscores the importance of CRF in the primary prevention of CVD in patients with hypercholesterolemia. Therefore, exploring the value of CRF as a marker of health in patients with familial hypercholesterolemia (FH) and how exercise interventions can improve CRF is of high scientific and clinical value.

Although exercise interventions can reduce inflammation, oxidative stress and improve endothelial function in different populations and is a cost-effective therapy with similar benefits to pharmacological treatment in reducing CV and all-cause mortality, its effects in patients with FH have not been addressed before. The UPPA-FH will unravel the role of high-intensity interval training (HIIT) versus moderate-intensity continuous training (MICT) on cardiorespiratory fitness and the course of atherosclerosis in men and women with FH. These interventions have proved to be effective in improving CRF and improve CVD risk factors, and HIIT has been shown to be a time-efficient intervention that increases adherence due to the limited amount of time needed and the clinically relevant benefits in patients with and without CVD. HIIT protocols also improve anthropometric, metabolic, and vascular function in people with type 1 diabetes, type 2 diabetes, coronary disease, obesity, or the general population. Furthermore, HIIT has been shown to be safe in patients with high CV risk, such as those with coronary disease and heart failure, when developed in supervised environments.

Unlocking how physical activity and fitness impact the development of atherosclerosis and the unique metabolomic signature of men and women with FH is a key goal of this proposal. But we're not stopping there. The UPPA-FH project goes one step further to uncover the specific effects of different exercise interventions and regimens on key health markers for FH, such as cardiorespiratory fitness and atherosclerosis, and to understand the underlying mechanisms for these benefits. This proposal has the potential to make breakthrough discoveries that will pave the way for future interventions and for developing clinical guidelines, including exercise recommendations for FH patients, which are currently lacking.

The novelty of this proposal relies on discovering the extent to which exercise can improve key health parameters in FM patients, which is currently unknown. The clinical guidelines for these patients lack specific information on physical activity and exercise, which limits the ability of the health care system to benefit this population. Based on evidence on many similar populations, it can be affirmed that exercise has a huge potential to improve critical markers in patients with FH. Another novelty of the UPPA-FH study is to unravel the mechanisms underlying the effects of exercise, including inflammatory markers, oxidative stress and the metabolomic signature. Finally, also a novelty of this study will be to address the safety of moderate and high intensity exercise in this special population of high CV risk by providing detailed information about the adverse effects of the interventions; the lack of adverse effects reporting in exercise trials is a very common issue that this study will clearly address. All in all, through a highly collaborative y multidisciplinary research approach team and design, this study will contribute to improve the current management of FH patients, and will allow to understand the reasons why exercise is beneficial in this genetic condition.

Tipo di studio

Interventistico

Iscrizione (Stimato)

75

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

    • Granada
      • Granada, Granada, Spagna, 18014
        • Reclutamento
        • Virgen de las Nieves University Hospital
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 70 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion criteria:

  • Individuals with a diagnosis of genetic FH.
  • > 18 years old.
  • Minimum follow-up of 1 year in the Vascular Risk Clinic of the Virgen de las Nieves University Hospital (HUVN).
  • Clinical and treatment stability.
  • Non-pathological angio-TAC of coronary arteries in the 2 years prior to the study (for participants >45 years old).

Exclusion criteria:

  • Inability to read, understand and sign the informed consent.
  • Contraindications to exercise.
  • History of clinical CVD (ischemic heart disease, stroke, and/or peripheral arterial disease).

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: High Intensity Interval Training (HIIT) intervention program

The HIIT protocol will involve 3 training sessions per week for 16 weeks (a total of 48 sessions lasting 36 minutes). The high-intensity intervals will follow the Norwegian 4 x 4-minute HIIT model: 4 bouts of 4 minutes of high intensity corresponding to a rating of perceived exertion (RPE) 15 to 18 on the Borg 6 to 20 Scale and an 85-95%HRmax, interspersed with 3-minute active recovery intervals (RPE of 11 to 13 and 54-69%HRmax).

The HIIT protocol will involve 3 training sessions per week for 16 weeks (a total of 48 sessions lasting 36 minutes). The program will be divided into two phases: phase 1 (adaptation to HIIT training: during the first 4 weeks, the intensity will be progressively increased to ensure the safety and progressive physical conditioning of the patients.

The high-intensity intervals will follow the Norwegian 4 x 4-minute HIIT model: 4 bouts of 4 minutes of high intensity corresponding to a rating of perceived exertion (RPE) 15 to 18 on the Borg 6 to 20 Scale33 and an 85-95%HRmax, interspersed with 3-minute active recovery intervals (RPE of 11 to 13 and 54-69%HRmax). This protocol has been widely applied and is safe in general and in clinical populations. Additionally, this protocol includes the training parameters recently proposed in a recent meta-analysis to maximize the training effects of HIIT on cardiorespiratory fitness (primary outcome).

Sperimentale: Moderate Intensity Continous Training (MICT) intervention program

The MICT protocol will involve 3 training sessions per week for 16 weeks (a total of 48 sessions lasting 44 minutes). The workout will be performed at RPE 11 to 13 (54-69%HRmax) to provide an isoenergetic workload (same energy expenditure) as the HIIT group

The MICT protocol will involve 3 training sessions per week for 16 weeks (a total of 48 sessions lasting 44 minutes). The workout will be performed at RPE 11 to 13 (54-69%HRmax) to provide an isoenergetic workload (same energy expenditure) as the HIIT group.

Each session will include 3 parts: warm-up (5 min), main MICT workout (34 min), and a cool-down (5 min). Warm-up will include mobility, core, and aerobic exercise involving major muscle groups. The main workout (MICT) will include exercises involving major muscle groups using the same materials and rationale as commented on in the HIIT group. The cool-down phase will include aerobic exercise at a lower intensity, stretching, and relaxation exercises (RPE<11). The highest and average HR and RPE for each session will be registered.

Nessun intervento: Control group

The control group will follow a usual care regime during the intervention and will not participate in supervised exercise. However, the participants randomized to this group will be invited to participate in a similar intervention once the study is completed (waiting list control group).

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Cardiorespiratory fitness
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Cardiorespiratory fitness will be assessed using the Bruce Protocol Ramp, a variation of the widely used Bruce Protocol. The test will be performed on a treadmill, with speed and incline progressively increasing every 15 seconds until exhaustion. Because CRF is the primary study outcome, maximal oxygen uptake will be continuously measured using the Vyntus CPT.

Before and after the training intervention or control (16 weeks).

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Vascular inflammation
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Will be evaluated by performing a PET-CT. This examination is performed with an integrated PET/CT scanner (Siemens Biograph Vision 600, from Siemens Healthcare®, Erlangen, Germany). The protocol for the preparation procedure, administration of the radiopharmaceutical and image acquisition will be based on the available international recommendations. Before the examination, the patient is subjected to a fast of at least 6 hours and adequate hydration, and should present a capillary glucose level lower than 6.8 mmol/L (122.51 mg/dL) at the time of radiopharmaceutical administration. The evaluation of the images will include a visual and semi-quantitative analysis by calculating the different metabolic quantitative parameters that include the SUV (Standard Uptake Value) normalized by body weight and lean mass (SUL) maximum. The regions of interest (ROIs) for the calculation of SUL will be: carotid arteries, aortic arch, abdominal aorta and common iliac arteries.

Before and after the training intervention or control (16 weeks).
Carotid Doppler Ultrasound
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Non-invasive technique that allows visualization of the walls of the carotid artery using ultrasound. The General Electric's Logic F6® ultrasound device will be used. The mean intima-media thickness (mean IMT, mm) will be used as a secondary outcome measure.

Before and after the training intervention or control (16 weeks).
Arterial Stiffness
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Evaluated by determining the VOP, which depends on arterial stiffness (the more speed the more stiffness). Its elevation is a early marker of atherosclerosis. The Mobil-O-Graph® 24h pulse wave monitor device (IEM GmbH, Stolberg, Germany), whose operation is based on oscillometry recorded by a blood pressure cuff placed on the brachial artery, will be used.

Before and after the training intervention or control (16 weeks).
IL-6
Lasso di tempo: Before and after the training intervention or control (16 weeks).

• Inflammatory marker: (pg/mL).

Before and after the training intervention or control (16 weeks).
Ultrasensitive PCR
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Inflammatory marker (mg/L).

Before and after the training intervention or control (16 weeks).
Fibrinogen
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Coagulation (mg/dL, von Clauss assay).

Before and after the training intervention or control (16 weeks).
Oxidized LDL
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Oxidative stress marker: (U/L)

Before and after the training intervention or control (16 weeks).
ICAM-1
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Endothelial dysfunction marker: (pg/mL)

Before and after the training intervention or control (16 weeks).
Low-Density Lipoprotein Cholesterol
Lasso di tempo: Before and after the training intervention or control (16 weeks).

LDLc (mg/dL)

Before and after the training intervention or control (16 weeks).
High-Density Lipoprotein Cholesterol
Lasso di tempo: Before and after the training intervention or control (16 weeks)

HDL-c (mg/dL)

Before and after the training intervention or control (16 weeks)
Triglycerides
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Lipid profile (mg/dL).

Before and after the training intervention or control (16 weeks).
Apolipoprotein B
Lasso di tempo: Before and after the training intervention or control (16 weeks).

ApoB (mg/dL)

Before and after the training intervention or control (16 weeks).
Lipoprotein(a)
Lasso di tempo: Before and after the training intervention or control (16 weeks)

Lp(a) (mg/dL)

Before and after the training intervention or control (16 weeks)
Fat percentage
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Total fat percentage will be measured by densitometry (DEXA).

Before and after the training intervention or control (16 weeks).
Visceral adipose tissue
Lasso di tempo: Before and after the training intervention or control (16 weeks)

Will be assessed by dual-energy X-ray absorptiometry (DXA) using a Discovery Wi system (Hologic, Bedford, MA, USA). Participants will be scanned in the supine posi-tion according to the manufacturer's standard protocol.

Before and after the training intervention or control (16 weeks)
Lean tissue
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Lean mass will be measured by densitometry (DEXA).

Before and after the training intervention or control (16 weeks).
Lower body strength
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Lower body strength will be evaluated using 30 Second Chair Stand Test.

Before and after the training intervention or control (16 weeks).
Risk of suffering a cardiovascular event in 5 and 10 years
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Will be estimated using the SAFEHEART-Risk Equation.

Before and after the training intervention or control (16 weeks).

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Age
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Years old.

Before and after the training intervention or control (16 weeks).
Education Level
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Categorical.

Before and after the training intervention or control (16 weeks).
Occupational status
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Categorical.

Before and after the training intervention or control (16 weeks).
Tobacco use
Lasso di tempo: Before and after the training intervention or control (16 weeks)

Categories: never smoker (never smoked or quit >12 months), former smoker (quit ≤12 months), current smoker (1-5, 6-10, 11-15, 16-20, or >20 cigarettes/day).

Before and after the training intervention or control (16 weeks)
Alcohol consumption
Lasso di tempo: Before and after the training intervention or control (16 weeks)

Categories: never, occasional (<weekly), frequent (weekly but not daily), daily.

Before and after the training intervention or control (16 weeks)
Medication use
Lasso di tempo: Before and after the training intervention or control (16 weeks)

Type and use (yes/no) of lipid-lowering therapy (statins, ezetimibe, PCSK9 inhibitors, bempedoic acid, colesevelam), antihypertensive medications, glucose-lowering medications, weight-management medications, anti-inflammatory medications, corticosteroids, beta-blockers, and other medications.

Before and after the training intervention or control (16 weeks)
Family and personal history of CVD
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Categorical.

Before and after the training intervention or control (16 weeks).
Metabolites: Carbohydrates (glucose).
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Acquisition of metabolomic profiles by Nuclear Magnetic Resonance (NMR) on a Bruker Avance Ascend HD 600 MHz spectrometer. The NMR profiles and other data will be analyzed by multivariate data analysis techniques to find relevant biomarkers and for the construction of predictive models. These analyses will be conducted at the University of Almería and a comprehensive lipidomic fingerprint will be performed by the BGI.inc in Hong Kong.

Before and after the training intervention or control (16 weeks).
Metabolites: Amino Acids
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Acquisition of metabolomic profiles by Nuclear Magnetic Resonance (NMR) on a Bruker Avance Ascend HD 600 MHz spectrometer. The NMR profiles and other data will be analyzed by multivariate data analysis techniques to find relevant biomarkers and for the construction of predictive models. These analyses will be conducted at the University of Almería and a comprehensive lipidomic fingerprint will be performed by the BGI.inc in Hong Kong.

Before and after the training intervention or control (16 weeks).
Metabolites: Derivatives
Lasso di tempo: Before and after the training intervention or control (16 weeks).

E.g., 3-hydroxybutyrate, creatine. Acquisition of metabolomic profiles by Nuclear Magnetic Resonance (NMR) on a Bruker Avance Ascend HD 600 MHz spectrometer. The NMR profiles and other data will be analyzed by multivariate data analysis techniques to find relevant biomarkers and for the construction of predictive models. These analyses will be conducted at the University of Almería and a comprehensive lipidomic fingerprint will be performed by the BGI.inc in Hong Kong.

Before and after the training intervention or control (16 weeks).
Metabolites: TCA cycle metabolites
Lasso di tempo: Before and after the training intervention or control (16 weeks).

E.g., citric acid, pyruvic acid. Acquisition of metabolomic profiles by Nuclear Magnetic Resonance (NMR) on a Bruker Avance Ascend HD 600 MHz spectrometer. The NMR profiles and other data will be analyzed by multivariate data analysis techniques to find relevant biomarkers and for the construction of predictive models. These analyses will be conducted at the University of Almería and a comprehensive lipidomic fingerprint will be performed by the BGI.inc in Hong Kong.

Before and after the training intervention or control (16 weeks).
Metabolites: Choline
Lasso di tempo: Before and after the training intervention or control (16 weeks).

(Cho)-based compounds (which are essential components of cellular membranes). Acquisition of metabolomic profiles by Nuclear Magnetic Resonance (NMR) on a Bruker Avance Ascend HD 600 MHz spectrometer. The NMR profiles and other data will be analyzed by multivariate data analysis techniques to find relevant biomarkers and for the construction of predictive models. These analyses will be conducted at the University of Almería and a comprehensive lipidomic fingerprint will be performed by the BGI.inc in Hong Kong.

Before and after the training intervention or control (16 weeks).
Metabolites: fatty acids and ketone bodies
Lasso di tempo: Before and after the training intervention or control (16 weeks).

E.g. 3-hydroxybutyrate, acetate, and acetoacetate. Acquisition of metabolomic profiles by Nuclear Magnetic Resonance (NMR) on a Bruker Avance Ascend HD 600 MHz spectrometer. The NMR profiles and other data will be analyzed by multivariate data analysis techniques to find relevant biomarkers and for the construction of predictive models. These analyses will be conducted at the University of Almería and a comprehensive lipidomic fingerprint will be performed by the BGI.inc in Hong Kong.

Before and after the training intervention or control (16 weeks).
Metabolites: Nucleotides/nucleosides, polyols
Lasso di tempo: Before and after the training intervention or control (16 weeks).

E.g., glycerol. Acquisition of metabolomic profiles by Nuclear Magnetic Resonance (NMR) on a Bruker Avance Ascend HD 600 MHz spectrometer. The NMR profiles and other data will be analyzed by multivariate data analysis techniques to find relevant biomarkers and for the construction of predictive models. These analyses will be conducted at the University of Almería and a comprehensive lipidomic fingerprint will be performed by the BGI.inc in Hong Kong.

Before and after the training intervention or control (16 weeks).
Vitamin D
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Parameter involved in muscle metabolism: (nmol/L).

Before and after the training intervention or control (16 weeks).
TSH
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Parameter involved in muscle metabolism (mUI/L).

Before and after the training intervention or control (16 weeks).
Glucose
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Glucose profile (mg/dL).

Before and after the training intervention or control (16 weeks).
Homocysteine
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Coagulation (μmol/l; AxSYM • Homocysteine; Abbott Laboratories, Abbott Park, IL).

Before and after the training intervention or control (16 weeks).
Urea
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Renal function (mg/dL).

Before and after the training intervention or control (16 weeks).
Creatinine
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Renal function (mg/dL).

Before and after the training intervention or control (16 weeks).
Microalbuminuria
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Determination of albumin in urine by nephelometry (Hy-Pro 50 protein analyzer) (mg/dL).

Before and after the training intervention or control (16 weeks).
Erythrocytes
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Hemogram (x 106/uL).

Before and after the training intervention or control (16 weeks).
Hemoglobin
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Hemogram (Hb, g/dL).

Before and after the training intervention or control (16 weeks).
Mean corpuscular volume
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Hemogram (VCM, fL).

Before and after the training intervention or control (16 weeks).
Leukocytes
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Hemogram (x 103/uL).

Before and after the training intervention or control (16 weeks).
Platelets
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Hemogram (x 103/uL).

Before and after the training intervention or control (16 weeks).
Diet
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Adherence to mediterranean diet will be evaluated using the PREDIMED questionnaire.

Before and after the training intervention or control (16 weeks).
Height
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Height will be measured in cm with 1mm precision (SECA 222).

Before and after the training intervention or control (16 weeks).
Weight
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Weight will be measured in kg (SECA 222).

Before and after the training intervention or control (16 weeks).
BMI
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Weight will be measured in kg and height in cm with 1mm precision (SECA 222), and BMI will be calculated (in kg/m2).

Before and after the training intervention or control (16 weeks).
Waist circunference
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Waist circumference will be measured by non-elastic anthropometric tape (SECA 200).

Before and after the training intervention or control (16 weeks).
Hip circumference
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Hip circumference will be measured by non-elastic anthropometric tape (SECA 200).

Before and after the training intervention or control (16 weeks).
Systolic and diastolic blood pressure
Lasso di tempo: Before and after the training intervention or control (16 weeks)

Systolic blood pressure (SBP) and diastolic blood pressure (DBP) will be measured using an automated digital blood pressure monitor manufactured by Omron Healthcare Europe B.V. (Hoofddorp, the Netherlands).

Before and after the training intervention or control (16 weeks)
Ventilatory thresholds (VT1 and VT2)
Lasso di tempo: Before and after the training intervention or control (16 weeks)

Cardiorespiratory fitness will be evaluated using the Bruce Ramp Protocol, a variation of the most widely used exercise testing protocol in cardiology. The first (VT1) and second (VT2) ventilatory thresholds will be determined from breath-by-breath respiratory gas exchange data and expressed as oxygen uptake (mL·kg-¹·min-¹). Heart rhythm will be continuously monitored using a 12-lead ECG, and blood pressure will be assessed throughout the test.

Before and after the training intervention or control (16 weeks)
Upper body strength
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Upper body strength will be evaluated using Hand Grip Strength (JAMAR dynamometer).

Before and after the training intervention or control (16 weeks).
Bone Mineral Density
Lasso di tempo: Before and after the training intervention or control (16 weeks)

Will be assessed by dual-energy X-ray absorptiometry (DXA) using a Discovery Wi system (Hologic, Bedford, MA, USA). Participants will be scanned in the supine position according to the manufacturer's standard protocol. Bone mineral density (BMD) will be expressed in g/cm² and as T-scores.

Before and after the training intervention or control (16 weeks)
Physical activity
Lasso di tempo: Before and after the training intervention or control (16 weeks).

It will be assessed with triaxial accelerometers (Axivity AX3, Axivity Ltd, United Kingdom). The AX3 has been validated and used to measure physical activity in a previous large-scale cohort study. Participants will use the accelerometer on the non-dominant wrist 24 hours a day for 10 consecutive days. A sampling frequency of 25 Hz will be set. Unprocessed accelerometry data will be downloaded as ".cwa" files and processed with R software using the GGIR package (v. 2.5-0, https://cran.r-project.org/web/packages/GGIR/). The most up-to-date validated cut-points will be used to classify time spent in light physical activity, moderate physical activity, vigorous physical activity, and very vigorous physical activity.

Before and after the training intervention or control (16 weeks).
Sedentary behaviour
Lasso di tempo: Before and after the training intervention or control (16 weeks).

It will be assessed with triaxial accelerometers (Axivity AX3, Axivity Ltd, United Kingdom). The AX3 has been validated and used to measure physical activity in a previous large-scale cohort study. Participants will use the accelerometer on the non-dominant wrist 24 hours a day for 10 consecutive days. A sampling frequency of 25 Hz will be set. Unprocessed accelerometry data will be downloaded as ".cwa" files and processed with R software using the GGIR package (v. 2.5-0, https://cran.r-project.org/web/packages/GGIR/). The most up-to-date validated cut-points will be used to classify time spent in Sedentary behaviour.

Before and after the training intervention or control (16 weeks).
Sleeping time
Lasso di tempo: Before and after the training intervention or control (16 weeks).

It will be assessed with triaxial accelerometers (Axivity AX3, Axivity Ltd, United Kingdom). The AX3 has been validated and used to measure physical activity in a previous large-scale cohort study. Participants will use the accelerometer on the non-dominant wrist 24 hours a day for 10 consecutive days. A sampling frequency of 25 Hz will be set. Unprocessed accelerometry data will be downloaded as ".cwa" files and processed with R software using the GGIR package (v. 2.5-0, https://cran.r-project.org/web/packages/GGIR/). The most up-to-date validated cut-points will be used to classify sleeping time.

Before and after the training intervention or control (16 weeks).
Anxiety
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Self-perceived levels on anxiety will be evaluated using the HADS questionnaire.

Before and after the training intervention or control (16 weeks).
Depression
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Self-perceived levels on depression will be evaluated using the HADS questionnaire.

Before and after the training intervention or control (16 weeks).
Health-related Quality of life
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Self-perceived levels of quality of life (Physical Summary Component and Mental Summary Component) will be evaluated using the SF-36 questionnaire.

Before and after the training intervention or control (16 weeks).
Physical Function
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Self-perceived levels of quality of life (physical function) will be evaluated using the SF-36 questionnaire.

Before and after the training intervention or control (16 weeks).
Physical Role
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Self-perceived levels of quality of life (physical role) will be evaluated using the SF-36 questionnaire.

Before and after the training intervention or control (16 weeks).
Bodily pain
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Self-perceived levels of quality of life (pain) will be evaluated using the SF-36 questionnaire

Before and after the training intervention or control (16 weeks).
General Health
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Self-perceived levels of quality of life (general health) will be evaluated using the SF-36 questionnaire.

Before and after the training intervention or control (16 weeks).
Vitality
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Self-perceived levels of quality of life (vitality) will be evaluated using the SF-36 questionnaire.

Before and after the training intervention or control (16 weeks).
Social Function
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Self-perceived levels of quality of life (social function) will be evaluated using the SF-36 questionnaire.

Before and after the training intervention or control (16 weeks).
Emotional Role
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Self-perceived levels of quality of life (emotional role) will be evaluated using the SF-36 questionnaire.

Before and after the training intervention or control (16 weeks).
Mental Health
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Self-perceived levels of quality of life (mental health) will be evaluated using the SF-36 questionnaire.

Before and after the training intervention or control (16 weeks).
Cognitive function
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Cognitive function will be evaluated with the Montreal Cognitive Assessment (MoCA).

Before and after the training intervention or control (16 weeks).
Visual and episodic memory
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Visual and episodic memory will be evaluated with the National Institute of Health (NIH) Toolbox, a multi-domain neuropsychological test battery tests that are administered digitally. In particular, the Picture Sequence Memory Test has been selected to define performance in visual and episodic memory.

Before and after the training intervention or control (16 weeks).
Working memory
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Working memory will be evaluated with the National Institute of Health (NIH) Toolbox, a multi-domain neuropsychological test battery tests that are administered digitally. In particular, the List Sort Working Memory Test has been selected to define performance in working memory.

Before and after the training intervention or control (16 weeks).
Inhibitory control and attention
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Inhibitory control and attention will be evaluated with the National Institute of Health (NIH) Toolbox, a multi-domain neuropsychological test battery tests that are administered digitally. In particular, the Flanker Test has been selected to define performance in inhibitory control and attention.

Before and after the training intervention or control (16 weeks).
Cognitive flexibility
Lasso di tempo: Before and after the training intervention or control (16 weeks).

Cognitive flexibility will be evaluated with the National Institute of Health (NIH) Toolbox, a multi-domain neuropsychological test battery tests that are administered digitally. In particular, the Dimensional Change Card Sort Test has been selected to define performance in cognitive flexibility.

Before and after the training intervention or control (16 weeks).

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Jose A Vargas-Hitos, MD, PHD, Virgen de las Nieves University Hospital, Granada, Spain
  • Investigatore principale: Alberto Soriano Maldonado, PhD, Universidad de Almeria

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

20 febbraio 2025

Completamento primario (Stimato)

28 febbraio 2027

Completamento dello studio (Stimato)

31 luglio 2027

Date di iscrizione allo studio

Primo inviato

27 gennaio 2025

Primo inviato che soddisfa i criteri di controllo qualità

13 febbraio 2025

Primo Inserito (Effettivo)

19 febbraio 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

22 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

18 settembre 2026

Ultimo verificato

1 gennaio 2026

Maggiori informazioni

Termini relativi a questo studio

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • PID2022-142844OB-I00

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

The study protocol and participant data are not publicly available due to ethical and privacy considerations. However, deidentified participant data may be made available by the corresponding author upon reasonable request, subject to institutional and ethical approvals.

Periodo di condivisione IPD

De-identified individual participant data may be available upon reasonable request after publication of the study results. Data will remain available subject to institutional and ethical approvals.

Criteri di accesso alla condivisione IPD

De-identified individual participant data may be made available to researchers upon reasonable request. Requests will be reviewed by the corresponding author and will be subject to institutional and ethical approvals. Data will only be provided when the proposed use is consistent with applicable ethical, privacy and data protection requirements.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .